Skip to content
Company Analysis

Xeris Biopharma Holdings, Inc. XERS

A comprehensive view of key metrics, scores, and financial health for Xeris Biopharma Holdings, Inc.

Overview of Xeris Biopharma Holdings, Inc.

XERS NMS
Healthcare Biotechnology Framework: Biotech / Pre-Revenue Small Cap
Xeris Biopharma Holdings, Inc. (XERS), is a Small Cap company, in the Biotechnology industry, last closed at $8.48, about 58.7% overvalued vs fair value, +13.2% 1Y return, placing in the top 10% of its sector.
Metrics P/E 2447.7× Rev Growth 43.7% ROE -7.0% Gross Margin 85.4%
USD 8.48
-0.59%
(Delayed)
• Vol 90d: 43.0%
52-Week Range
Market Cap
$1.49B
Enterprise Value
$1.66B
Overall Score
View breakdown
Overall
Growth
Good
Profitability
Good
Health
Good
Efficiency
Good
Valuation
Excellent
Growth
Good
Profitability
Good
Health
Good
Efficiency
Good
Valuation
Excellent
Completeness: 100%
Confidence: 62%
Updated: Sep 12
Top Beats

Quick Facts

Website https://www.xerispharma.com
HQ Chicago, IL
Employees 435
Fiscal year Dec 31

Next Events

Earnings Nov 5 Estimated

Fair Value Snapshot

Bear Base Bull
$3
$4
$4
Current: $8.48 -59% vs base

Engine Room Money Flow™

Small Cap

Biotech / Pre-Revenue - Where revenue goes and how value is created

Flow Steps
Cash on Hand
$111.0M
55%%
Total Revenue
$291.8M
43.7%%
Net Income
$554.0K
101%%
Operating Expense
$224.4M
12.3%%
Money Flow Bridge
Flow Direction: Money moves from left to right
Components: Breakdown shows composition of each stage
Industry-Specific: Biotech / Pre-Revenue

Quality & Reliability Indicators

R&D Intensity
13.9%
Poor

Low R&D intensity for a biotech - potential concern

Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium
Locked Metric
-
Premium

Where It Leaks

Cash Flow Health critical
Significant cash flow inefficiencies identified. Multiple high-impact leaks require attention.
1
Active Leaks
0/1
Improving
0
High Impact
1
Critical
Moat Analysis Corporate Default

Competitive Advantage Assessment

Evaluating Xeris Biopharma Holdings, Inc.'s durable competitive advantages across 6 defense dimensions

Overall Moat Strength
64
/100
Moderate
Scores based on quantitative metrics and qualitative factors
Full moat analysis

Key strengths

  • Margins Stable Across Cycles Operating margin volatility is low (stability score 0.82), demonstrating pricing resilience across cycles.
  • Cost Leadership Position Operating margin at 88.6th percentile with strong OpEx control demonstrates cost leadership.

Key risks

  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.16), suggesting weak customer stickiness.
  • Liquidity Concerns Liquidity is concerning (score 0.25), raising questions about short-term obligations.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Moderate
72
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.
Premium
Unlock full defense details

See key signals plus strengths and risks for this moat dimension.

Upgrade for full defense analysis Premium-only evidence and insights.
For informational purposes only. Not investment advice.

Trade-Off Ledger

Where management spends the performance budget

Insufficient Data for Analysis

XERS - Xeris Biopharma Holdings, Inc.

We have limited financial data for XERS. The Growth and Profitability axes don't have enough metrics for reliable analysis.

Data Coverage by Axis

Growth
0% coverage Below threshold
Profitability
0% coverage N/A
Overall Coverage: 33.3% (Minimum 40% required)

What This Means

  • Currently at 33.3% data coverage (minimum 40% required)
  • Limited peer data available for industry benchmarking
  • Check back after quarterly or annual filings
  • Some metrics may not be applicable to this company's business model

What can you do?

  • View available sections like Moat Map or Engine Room for partial insights
  • Set up a watchlist alert to be notified when new data becomes available
  • Compare with peers in the same industry that have complete data

Two Futures

Scenario-based fair value ranges for Xeris Biopharma Holdings, Inc..

Loading valuation model...
Unable to Compute Fair Value

This company cannot be valued using standard models.

What this means: The Scenario Theatre requires financial data (revenue, cash flow, shares outstanding) to calculate fair value estimates. This data may be unavailable for:

  • Recently listed companies (IPOs, SPACs)
  • Shell companies or holding companies
  • Companies that haven't filed recent financials
  • Foreign companies with limited data coverage
X.X%
X%XX%
X.X%
-XX%XX%
XX.X%
-XX%XX%
Adjust the sliders above to explore different valuation scenarios.
Unlock Premium
Reveal the full Scenario Theatre
See live sliders, narratives, and full Bear/Base/Bull outcomes.
Upgrade Now
Bear
-
- - -
- upside
-
Base
$3.50
- - -
-58.7% vs current
Snapshot base estimate
Bull
-
- - -
- upside
-
Fair Value Range Current: $-
$- $- $-
Actions & Info
Send Feedback
Please select a category.
0/1000